Biotechnology company Gero, specializing in AI-powered drug discovery and longevity research, made a significant contribution to the global scientific community on June 25, 2025, by open-sourcing its new AI model, ProtoBind-Diff. As stated in the companys press release, the model and its accompanying code have been published on the GitHub platform, making them accessible to researchers worldwide. ProtoBind-Diff is a generative diffusion model designed to solve one of the key and most complex challenges in modern pharmaceuticals: accurately predicting how small molecules (potential drugs) will bind to specific target proteins in the human body. Efficiently modeling this protein-ligand binding process allows for the rapid screening of ineffective compounds at early stages and focuses efforts on the most promising candidates, potentially saving years and millions of dollars in research and development (R&D) time and costs. Geros decision to make this powerful and modern model fully open-source is of great significance to the entire industry. It provides academic researchers, university labs, and small biotech startups around the world with access to a cutting-edge tool that was previously available only to large pharmaceutical corporations with their vast computational resources and teams of specialists. This move promotes the democratization of research and could spur new discoveries in the treatment of a wide range of diseases. This release also strengthens Geros reputation as a company committed to the principles of open science and using artificial intelligence to solve fundamental healthcare problems.
Gero Releases Open-Source ProtoBind-Diff Model to Accelerate Drug Discovery
